Soligenix, Inc. — FY2021 Form 10-K Summary
Reporting period: Year ended December 31, 2021; filed March 29, 2022. This is an annual report, not a standalone fourth-quarter report. Soligenix is a clinical-stage biopharmaceutical company with Specialized BioTherapeutics and Public Health Solutions segments. It had no approved products and relied primarily on government grants and contracts, equity financing, and debt.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue, primarily government contract and grant revenue | $824,268 | $2,359,447 |
| Gross profit (margin) | $95,628 (12%) | $538,498 (23%) |
| Research and development expense | $8,389,387 | $9,796,167 |
| General and administrative expense | $4,847,126 | $4,328,838 |
| Operating loss | $13,140,885 | $18,586,507 |
| Net loss | $12,550,973 | $17,688,522 |
| Basic and diluted loss per share | $0.31 | $0.64 |
| Net cash used in operating activities | $11,739,620 | $11,454,426 |
| Cash and cash equivalents at year-end | $26,043,897 | $18,676,663 |
| Working capital at year-end | $20,278,345 | $13,386,485 |
Revenue fell 65%, mainly as government contracts and grants concluded; gross profit also declined, in part reflecting the end of CTCL study activity. R&D expense decreased 14% following completion of the HyBryte and SGX942 Phase 3 studies. Net loss improved 29%, primarily because FY2020 included a $5 million stock-based Hy Biopharma milestone expense. FY2021 also included $421,584 of PPP loan forgiveness income and an $864,742 New Jersey NOL-sale tax benefit.
At year-end, total liabilities were $16.1 million, including $9.9 million of convertible debt net of discount. The company had borrowed $10 million under the Pontifax facility; the debt bears 8.47% interest, is secured by substantially all assets other than intellectual property, has an interest-only period through December 2022, and matures June 15, 2025. The remaining $5 million tranches expired unused. Operating cash flow was negative, while financing activities included $19.7 million of gross ATM equity proceeds; shares outstanding rose from 30.6 million to 42.9 million during 2021.
Pipeline, changes, and outlook
- HyBryte (synthetic hypericin) for CTCL: The completed Phase 3 FLASH study met its primary endpoint at eight weeks (16% response versus 4% with placebo; p=0.04). The company reported higher response with longer treatment, including 49% among a subset treated for 18 weeks. The NDA filing target moved to the second half of 2022, with potential FDA approval in the second half of 2023, after a contract manufacturer delay affected required stability data. These are targets, not assured outcomes.
- SGX942 (dusquetide) for oral mucositis: The Phase 3 DOM-INNATE trial missed its prespecified primary endpoint for statistical significance, despite a reported median severe-mucositis duration of 8 days versus 18 days for placebo. Following MHRA feedback, a second Phase 3 study would be needed to support potential marketing authorization. Soligenix plans to analyze the dataset, design another trial, and seek a partner.
- Other programs: A Phase 2a psoriasis study of SGX302 was anticipated in the second half of 2022. SGX203 for pediatric Crohn’s disease remained dependent on additional funding or partnership. Public Health Solutions programs—including RiVax, CiVax, filovirus vaccines, ThermoVax, and SGX943—remained at clinical or preclinical stages and depended substantially on government support.
- 2022 spending and liquidity outlook: Planned R&D expenditure was approximately $12.9 million before reimbursements, with about $1.3 million expected to be reimbursed. Management said available cash, expected grant and contract receipts, and ATM capacity were expected to support operations for at least 12 months from issuance of the financial statements; another disclosure projected operations through at least March 31, 2023. Continued funding, partnerships, or additional capital may be needed.
Risks, contingencies, and unusual items
- The company has an accumulated deficit of approximately $205.8 million, recurring losses, no product sales, and substantial dependence on future financing, government funding, partnerships, or equity issuance. Further equity could dilute shareholders.
- In July 2020, Soligenix initiated arbitration against Emergent BioSolutions and subsidiaries over alleged manufacturing and quality failures involving RiVax drug substance. The company seeks more than $19 million; Emergent denies the allegations. Recovery is uncertain. The Phase 1c RiVax study was suspended in January 2020 after the manufacturer reported an out-of-specification issue; two participants had received doses, with no safety issues reported.
- COVID-19 did not have a material impact on FY2021 results, but the filing cites possible future effects on sourcing, manufacturing, clinical operations, and regulatory timelines. A separate HyBryte API-manufacturing delay contributed to the NDA schedule change.
- Manufacturing is outsourced, and drug substances currently rely on single suppliers. Regulatory approval, clinical success, market acceptance, reimbursement, and the ability to obtain government procurement remain uncertain.
- Nasdaq notified the company in December 2021 that its share price was below the $1 minimum bid requirement. The stated initial compliance deadline was June 20, 2022; a reverse split was among possible remedies if needed.
- The 2015 equity plan had no shares remaining for new grants at year-end. The filing also disclosed outstanding warrants, options, convertible debt, and remaining ATM capacity that could contribute to dilution.
Important facts for investors to verify
- Whether HyBryte’s NDA was filed on the revised timetable, and the FDA’s review requirements, decision timing, and any additional manufacturing or stability-data issues.
- Whether additional funding or a partner was secured for the proposed SGX942 Phase 3 trial and for other underfunded pipeline programs.
- Current cash, operating cash burn, grant availability, ATM usage, and any financing since the March 2022 filing; assess runway against planned 2022 spending.
- Current Pontifax debt balance, interest and repayment terms, covenant compliance, and any consequences of the unused tranches expiring.
- Developments and potential financial effects of the Emergent arbitration, including the disputed approximately $331,000 in invoices and the uncertain claim for damages exceeding $19 million.
- Nasdaq listing compliance status, share-count changes, and potential dilution from equity awards, warrants, convertible securities, and ATM sales.